HBOT Conversations:
Dr. Paul Harch & Birth Injuries/ Cerebral Palsy
Dr. Paul G. Harch, M.D. has used hyperbaric oxygen therapy to treat more than 100 different conditions, including stroke, dementia, autism, and traumatic brain injury. His goal is to help his patients get their lives back using hyperbaric oxygen therapy.
He is the author of The Oxygen Revolution and is considered an International expert and pioneer in the field of Hyperbaric Oxygen Therapy (HBOT). His informative, and comprehensive guide on HBOT has helped countless souls better understand what HBOT is and how it directly affects the body at the genetic level.
This episode on birth injuries with a strong focus on Cerebral Palsy (CP) is the fifth in a nine episode series that will be released weekly with Dr. Harch.
Watch the Podcast
In episode 5 of 9, host Edward di Girolamo speaks with world renowned HBOT expert, Dr. Paul G. Harch about birth injuries and Cerebral Palsy (Chapter 5 of his book, The Oxygen Revolution).
In Dr. Harch’s book he describes the trip down the birth canal as one of the most high-risk journeys any human will ever make. Dr. Harch educates us on how traumatic birth experiences can trigger Cerebral Palsy diagnoses in young infants, and how premature babies are at great risk for Cerebral Palsy since they are born with the center of the brain undeveloped, still very fragile and prone to spontaneous bleeding.
Every day desperate parents around the world seek alternative healing therapies for their children with cerebral palsy. Dr. Harch dives deep into the use of Hyperbaric Oxygen Therapy (HBOT) for the treatment of Cerebral Palsy and other neurological birth disorders, and explains the reasons why parents should embrace this therapy. Essentially, Dr. Harch describes Cerebral Palsy as a wound to the brain, so it should respond to Hyperbaric Oxygen Therapy the same way as other brain injuries. He confers that it absolutely does.
Dr. Harch reveals success stories of CP children who have had found hope and new life from Hyperbarics. In response to these stories and hearing that it works to heal and ease life-long debilitating CP symptoms, di Girolamo wants to know why more parents aren’t seeking out HBOT to help their cerebral palsy children? Harch relays that there’s too much inconsistent medical literature out there, and in many ways it’s just plain wrong. For example, a parent asks their doctor, “How about HBOT to treat Cerebral Palsy?”— the doctor might be unfamiliar with the therapy, so he/she checks the online medical database for HBOT and CP. Unfortunately this doctor will likely find some skewed data, leading the doctor to respond with “so….. I don’t think it’ll help”. Although, as Dr. Harch explains, the exact opposite is what’s true; HBOT absolutely helps CP patients.
One example given is that a well respected peer-reviewed medical journal, The Lancet, published medical literature on HBOT and CP announcing there was no proven benefit to use Hyperbaric Oxygen Therapy to treat Cerebral Palsy. But, the inconsistency there was that the control group was defined as a placebo, and that was not right. In response, Dr. Pierre Marois and his team, released a retrospective study on HBOT in the treatment of Cerebral Palsy that showed studies and numerous reports demonstrating the positive effects of Hyperbaric Oxygen Therapy (HBOT) in children with Cerebral Palsy.
Dr. Harch suggests our viewers dive into his 2021 presentation at the Team Luke3 Hope for Minds pediatric brain injury conference. Dr. Harch provided a summarization of all of the science showing that Hyperbaric Oxygen Therapy had extremely positive effects on every stage of the stem cell process. Additionally, Dr. Proefrock’s presentation from the same conference, “Current Trends in Naturopathic Treatment of Pediatric Neurological Injury” reveals stem cell data for children in the midst of HBOT treatment; showing that the children who have had Hyperbaric treatments produced 4x the amount of stem cells compared to those who did not.
Dr. Harch explains the roadblock for using Hyperbaric Oxygen for treatment of CP is still extremely difficult to get around, and he references the 2012 article by Novak and Badawai, Last breath: effectiveness of hyperbaric oxygen treatment for Cerebral Palsy as an example. In this article, they concluded that “Hyperbaric Oxygen does not have a clinically important effect on gross motor and self-care function in children with Cerebral Palsy.” Dr. Harch clarifies why they were wrong on the science, and how information like that is what’s preventing the average medical doctor to recommend HBOT for Cerebral Palsy.
di Girolamo and Dr. Harch urges viewers to find out for themselves if HBOT could be a good therapy for them or their loved one(s) living with CP. If you would like to dive into the world of Hyperbaric Oxygen Therapy for the treatment of Cerebral Palsy, HBOT News encourages you to find a licensed Hyperbaric Oxygen Therapy facility with hard mono-chambers or hard multi-place chambers, and act on this responsibly. Just like anything in the world of modern medicine, you can be injured or do more harm than good if HBOT is not administered correctly.
All of the data and success stories Dr. Harch reveals paints a much different picture than what the medical industry is showing us. Go try Hyperbaric Oxygen Therapy sooner than later to treat, heal, and ease the symptoms of Cerebral Palsy. We trust that HBOT can also change your life!
Subscribe Now, It’s Free !
Guest
Dr. Paul G. Harch, MD
Dr. Harch initiated and continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice, he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system, which spawned the subsequent academic and research practice. Harch HBOT is the best place to receive oxygen therapy treatments, and patients have traveled from more than 50 countries to be treated by Dr. Harch himself.
Harch HBOT – Hyperbaric Oxygen Therapy Clinic
5216 Lapalco Blvd.
Marrero, LA
504-309-4948
hbot@hbot.com
https://hbot.com/
Recent HBOT News
Clinical Trial – Dose and Response of Intrathecal Hydromorphone in Patients Undergoing Cesarean Section at Virginia Commonwealth University Health System
In the United States the incidence of cesarean deliveries have increased over the last
several decades and is currently approximately 30% nationwide. The anesthesia and analgesia
for elective c-sections vary between institutions.
Parturients present a unique challenge for the anesthesiologist as the mother has to care not
only for herself, but also for the newborn postpartum. While intrathecal opioids provide
adequate pain relief, they do so at the cost of bothersome side effects for patients, such as
pruritus and nausea/vomiting.
Intrathecal hydromorphone has started to be explored as a new option for intrathecal
analgesia. A study done by Beatty et al. showed in a retrospective review that 40 mcg of
intrathecal dilaudid was safe and effective as compared to intrathecal morphine for analgesia
after cesarean delivery. Additionally they showed no difference in side effect profiles of
the two medications. Mhyre et al. investigated the use of 100 mcg of intrathecal dilaudid
with hyperbaric bupivacaine in varying dosages for labor analgesia. The results were
inconclusive, but the dosage of hydromorphone was reported to be without adverse effects.
Virginia Commonwealth University Health Systems has successfully instituted the use of
intrathecal morphine with superior analgesia but with undesired side effects, most notably
pruritus. Recent drug shortages of duramorph have prompted investigators to seek alternative
options for post cesarean section analgesia. The investigators are interested in determining
the dose, efficacy, and side effect profile of intrathecal hydromorphone. Although our
institution has never utilized intrathecal hydromorphone for our patient population, it has
been studied at various other institutions where it has been found to be safe and efficacious
with an acceptable side effect profile.
Repeat spinal anesthesia in cesarean section: A comparison between 10 mg and 12 mg doses of intrathecal hyperbaric (0.05%) bupivacaine repeated after failed spinal anesthesia: A prospective, parallel group study.
Abstract: Spinal anesthesia for cesarean section is not a 100% successful technique. At times, despite straightforward insertion and drug administration, intrathecal anesthesia for cesarean section fails to obtain any sensory or motor block. Very few studies and...
Endocan reduces the malign grade of gastric cancer cells by regulating associated protein expression.
Abstract: Endocan, which has been identified to be low expressed in gastric cancer, was found to be positively related to the differentiation level of gastric cancer in vivo and in vitro. In the present study, we aimed to investigate the role of endocan in gastric...